Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash from Operations came in at $8.6 billion in Q2 2026, up 122.18% year-over-year from $3.9 billion in Q2 2025, and up 242.72% quarter-over-quarter from $2.5 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash from Operations across 18 years of filings, most recently posting $8.6 billion for Q2 2026.
- In Q2 2026, Cash from Operations rose 122.18% year-over-year to $8.6 billion; the TTM figure through Jun 2026 stood at $27.6 billion (up 19.89% YoY), while the FY2025 annual figure was $24.5 billion, up 1.09% from the prior year.
- Cash from Operations came in at $8.6 billion for Q2 2026 at Johnson & Johnson, up from $2.5 billion in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of $9.2 billion in Q3 2025 to a low of $2.5 billion in Q1 2026.
- Average Cash from Operations over 5 years is $5.6 billion, with a median of $4.9 billion recorded in 2023.
- Year-over-year, Cash from Operations surged 123.63% in 2023 and sank 39.77% in 2026.
- Over 5 years, Cash from Operations stood at $4.0 billion in 2022, then soared by 97.61% to $7.9 billion in 2023, then decreased by 11.19% to $7.0 billion in 2024, then grew by 4.67% to $7.3 billion in 2025, then advanced by 17.88% to $8.6 billion in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were $8.6 billion in Q2 2026, $2.5 billion in Q1 2026, and $7.3 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 835.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 3.39 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 3.44 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -387.32 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 462.82 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 507.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 8.62 Bn |
| Mar 29, 2026 | 2.51 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Dec 31, 2023 | 7.86 Bn |
| Oct 1, 2023 | 7.49 Bn |
| Jul 2, 2023 | 4.18 Bn |
| Apr 2, 2023 | 3.26 Bn |
| Jan 1, 2023 | 3.52 Bn |
| Apr 3, 2022 | 3.98 Bn |
| Oct 3, 2021 | 8.29 Bn |
| Jul 4, 2021 | 5.31 Bn |
| Apr 4, 2021 | 4.07 Bn |
| Jan 3, 2021 | 8.34 Bn |